Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1/2 study of Adeno-Associated Virus Gene Therapy candidate rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Next Previous
Trial Profile

A phase 1/2 study of Adeno-Associated Virus Gene Therapy candidate rhodopsin-mediated autosomal dominant Retinitis pigmentosa

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Sep 2018

At a glance

  • Drugs Gene therapies (Primary)
  • Indications Retinitis pigmentosa
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors OphthoTech Corporation

    • Most Recent Events

    • 06 Sep 2018 New trial record
    • 22 Aug 2018 According to an OphthoTech Corporation media release, this phase 1/2 study is expected to start in 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top